Circio Holding ASA · OSL:CRNA
Circio Holding ASA — H1 2023 Earnings Presentation
21 slides from Circio Holding ASA's earnings presentation, Aug 24, 2023
Slide 1: First half 2023 presentation
circio fre First half 2023 *e, presentation 24 August 2023
Slide 2: Forward-looking statements
This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the results of operations and the financial condition of Circio Holding ASA and the C
Slide 3: First half 2023 highlights
: a strategic shift was announced to prioritize and accelerate the circRNA program over the legacy clinical stage immunotherapy programs : The company was rebranded as Circio, with new OSE ticker CRNA : Technical proof-of-concept was established for novel circVec vector designs, including demonstrat
Slide 4: NOK 300M financing facility
#1 NOK 37.5M 36 months Circio decides NOK 300M #2 NOK 30M 1 tranche every when to call on #3→ NOK 25M 3 months new capital 4
Slide 5: NOK 21.5m financing installments
#1 NOK 7.5m 1 Sep´23 8% per agreement NOK 21.5m #2 NOK 7m 15 Oct´23 + NOK 500k per #3 NOK 7m 1 Dec´23 installment* * To compensate for increased risk due to low trading volume 5
Slide 6: Financial update
Financial update 2. circRNA update 6 eircio
Slide 7: Income statement and cash, 1H22 to 1H23
NOK m 1H22 2H22 1H23 Total revenue 0 10 0 R&D expenses1 -23 .-24 -42 Payroll and related expenses -30 -22 -22 Other operation expenses2 -7 -398 -8 Total operating expenses -60 -444 -73 Operation loss -60 -434 -73 Net financial items 0 -2 -3 Loss before income tax -60 -436 -76 Net change in cash -56
Slide 8: Key figures and shareholder base
Key figures Shareholder base - 35 -3 Estimated ownership1 Net cash Shareholder Shares million Ownership flow in 1H NOK million USD million Høse AS 11.7 5.8 % Nordnet Bank AB (nom.) 5.6 2.8 % Bækkelaget Holding 5.5 2.7 % Cash at end of 1H 31 2.9 Andreassen, Jon-Arild Goldman Sachs Int (nom.) 5.2 5.2
Slide 9: circRNA update
circRNA update 9 circio
Slide 10: Total deal value of RNA-based private financings
$1,287M Total deal value of RNA-based $1,187M private financings $91 $52 $M, by RNA Modality Subtype $220 $976M $401 $51 $211 circRNA represented $24 $291 >40% of the total deal $107 $173 value of all private RNA $478M $80 $334M financings in 2021-23 $289M $104 $347 $16 $159 $570 $570 $13 $49 $7 $30
Slide 11: circRNA financing and licensing deals
Licensing Series A Series A Series A+B $150M Upfront $490M $3,5B Total deal value $270M $300M May/Aug 2021 Aug 2022 April 2023 May 2023 Feb 2021 Jul 2022 Aug 2022 Oct 2022 $80M $42M $221M Undisclosed Series A Series A Series B M&A 11
Slide 12: circRNA provides a toolbox for a novel class of medicines
circRNA provides a toolbox to create a novel class of medicines a Enhanced protein 1G Extended RNA ~ (@) expression i durability exonuclease degradation, leading to significantly improved half-life vs. » > microRNA Regulatory « 7 © sponging functionality
Slide 13: circVec mechanism
` circVec DNA or viral vector DNA Inject circRNA biogenesis circRNA Intra-cellular protein expression 13
Slide 14: circVec features
Strong transcription rate Best known circRNA biogenesis In-built RNAi functionality Vector agnostic – applicable to a variety of DNA and viral systems + IP filed 4Q´22 15x extended half-life vs. mRNA Enhanced and prolonged protein expression Sponging of miRNAs Regulatory functionality 14
Slide 15: circRNA outperforms mRNA in vitro
Accumulation of circVec circRNA and protein payload over time, RT-PCR and Western blot circVec RNA stability RT-qPCR, nascent vs. total RNA RNA expression protein expression circRNA outperforms mRNA in vitro – confirmatory in vivo experiments ongoing 15
Slide 16: Screening of natural circRNA-producing sequences
` mRNA AAAAAAAA Screening of most effective circRNA-producing sequences invented by nature Linear splicing circRNA protein Backsplicing 5 expression expression circRNA 4 / GAPDH L2 L1 L3 L4 Expression of endogenous circRNA 3 NGS analysis of 300+ RNAseq datasets 2 ⍺-ORF 1 ⍺-Ctrl 0 IR1 IR2 IR3 IR4 Top
Slide 17: Design optimization for circRNA biogenesis
Design optimization for circRNA biogenesis Efficient circRNA designs outperform mRNA circRNA-specific RT-PCR Western blot, protein expression 400 5x improvement on 300 top natural locus 300 200 / GAPDH 200 100 Payload 100 00 1 2 3 4 5 6 7 8 IR 9 IR 0 11 1_ 1_ 1_ 1_ 1_ 1_ 1_ 1_ 1_ 1 1_ 1_ Control IR
Slide 18: circVec designed for intra-cellular circRNA supply
Designed for intra-cellular circRNA supply, durable protein expression and targeted regulatory functionality 18
Slide 19: Rare disease indication prioritization
Rare Disease Initial Screening n Ipsum Lorem = 363 • Therapeutic Focus: Rare genetic disorders • Development Stage: Clinical or Market validation achieved 1st Prioritization Criteria n= Lorem 127 Ipsum • Etiology: monogenic disorders only (exclude polygenic disorders) • In vivo validation: availabil
Slide 20: 2023 in vivo study timeline
2023 Apr May Jun Jul Aug Sep Oct Nov Dec Transgene 1 durability circRNA vs. mRNA protein expression level and durability – Intra-tumoral injection of viral vectors expressing luciferase reporter from circRNA vs. mRNA Cancer Gene Therapy circVac circRNA vs. mRNA immune responses 2 Vaccine efficacy Im
Slide 21: circRNA platform summary and upcoming data
World-leading experts in-house with over 10 years experience in circRNA biology Led by circRNA discoverer and pioneer Dr. Thomas B Hansen Differentiated vector delivery platform opening new therapeutic areas for circRNA Potential applications in rare disease, cancer gene therapy and vaccines Efficie